Here’s a comparison table between the TC regimen (Docetaxel + Cyclophosphamide) and AC→T regimen (Doxorubicin + Cyclophosphamide followed by Paclitaxel) tailored for an oncology pharmacist:
| Feature | TC Regimen | AC→T Regimen |
|---|---|---|
| Components | Docetaxel + Cyclophosphamide | Doxorubicin + Cyclophosphamide → Paclitaxel |
| Typical Schedule | TC q3wk × 4 cycles | AC q3wk × 4 cycles → Paclitaxel q1wk × 12 or q2wk × 4 |
| Main Indications | Early-stage, HER2-negative breast cancer (node-negative or low-risk node-positive), patients unsuitable for anthracyclines | Early-stage or locally advanced, HER2-negative breast cancer (especially higher-risk), often standard in younger/fit patients |
| Efficacy (relative) | Effective in low–intermediate-risk disease; non-inferior to anthracyclines in some studies for certain subgroups | Often preferred for higher-risk disease; robust survival benefit in multiple trials |
| Anthracycline Use | No → avoids anthracycline-related toxicities | Yes → doxorubicin in AC phase |
| Key Advantages | Less cardiotoxicity; shorter treatment duration; simpler regimen | Higher efficacy in high-risk disease; strong evidence base |
| Key Disadvantages | More myelosuppression & febrile neutropenia risk (due to docetaxel) | Cardiotoxicity risk (doxorubicin); alopecia; longer overall treatment time |
| Notable Toxicities | Neutropenia, febrile neutropenia, fatigue, mucositis, nail changes, edema, neuropathy (less than paclitaxel) | Cardiotoxicity (acute & delayed), myelosuppression, neuropathy (from paclitaxel), alopecia, infusion reactions (paclitaxel) |
| G-CSF Prophylaxis | Strongly recommended (high FN risk, esp. in older adults) | Considered for AC if high FN risk; often given during dose-dense T phase |
| Cardiac Monitoring | Not routinely needed | Baseline LVEF (echocardiogram or MUGA) before starting anthracyclines |
| Duration | ~12 weeks | ~20–24 weeks (depending on paclitaxel schedule) |
| Preferred In | Patients with cardiac risk, elderly, low–intermediate-risk disease | Fit patients with high-risk disease, younger age, high tumor burden |